Skip to main content

Find Clinical Trials

Home
Conditions
Whooping Cough

Clinical trial condition

Whooping Cough

Explore clinical trials studying Whooping Cough. Study availability and eligibility vary by location and protocol.

231 public trials 8 recruiting studies

Refine in advanced search Browse all conditions

Whooping Cough trial results

Completed

A Study to Assess the Immunogenicity and Safety of GSK Biologicals' Infanrix-IPV/Hib Vaccine Administered as a Three-dose Vaccination Course at 3, 4.5 and 6 Months of Age and a Booster Dose at 18 Months of Age in Healthy Infants in Russia

NCT02858440

Conditions: Actinomycetales Infections, Bacterial Infections, Bacterial Infections and Mycoses, +25 more
Locations: GSK Investigational Site Barnaul, Russia

GSK Investigational Site Murmansk, Russia

GSK Investigational Site Saint Petersburg, Russia

GSK Investigational Site Tomsk, Russia

View Trial Details

Completed

A Study to Compare LBVD to Eupenta and Imovax Polio in Healthy Adults

NCT03208101

Conditions: Actinomycetales Infections, Bacterial Infections, Bacterial Infections and Mycoses, +36 more
Locations: Korea University Guro Hospital Seoul, South Korea

View Trial Details

Completed

Pertussis Infection in Adolescents and Adults With Prolonged Cough

NCT01597687

Conditions: Bacterial Infections, Bacterial Infections and Mycoses, Bordetella Infections, +6 more
Locations: GSK Investigational Site Kuala Lumpur, Malaysia

GSK Investigational Site Seremban, Malaysia

GSK Investigational Site Taichung, Taiwan

GSK Investigational Site Taoyuan, Taiwan

View Trial Details

Completed

Study to Assess Seroprevalence of Hepatitis A, Hepatitis B and Bordetella Pertussis in Mexico

NCT02112890

Conditions: Bacterial Infections, Bacterial Infections and Mycoses, Bordetella Infections, +15 more
Locations: GSK Investigational Site Cuernavaca, Morelos, Mexico

View Trial Details

Completed

The Transparent Safety Study of the 5 in 1 (DTwP-rHepB-Hib) Combination Vaccine Produced by the Indian Serine Institute in Children of Viet Nam Healthy From 6 to 12 Weeks of Age in a 3-dose Regimen, the Interval Between Doses is 4 Weeks

NCT03931239

Conditions: Actinomycetales Infections, Bacterial Infections, Bacterial Infections and Mycoses, +25 more
Locations: Hung Yen, Kim Dong Hung Yen, Vietnam

View Trial Details

Completed

Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4 and 12 Months (V419-007)

NCT01341639

Conditions: Actinomycetales Infections, Bacterial Infections, Bacterial Infections and Mycoses, +34 more
Locations: Not specified

View Trial Details

Completed

Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)

NCT01480258

Conditions: Actinomycetales Infections, Bacterial Infections, Bacterial Infections and Mycoses, +34 more
Locations: Not specified

View Trial Details

Completed

Pertussis and Meningitis C Concomitant Vaccination in Adolescents

NCT02526394

Conditions: Bacterial Infections, Bacterial Infections and Mycoses, Bordetella Infections, +11 more
Locations: Gloucestershire primary care Gloucestershire, United Kingdom

Hertfordshire primary care Hertfordshire, United Kingdom

View Trial Details

Completed

Study to Evaluate the Safety of Co-administration of GSK Biologicals' Poliorix and Infanrix in Healthy Children in Russia

NCT01094171

Conditions: Actinomycetales Infections, Bacterial Infections, Bacterial Infections and Mycoses, +23 more
Locations: GSK Investigational Site Barnaul, Russia

GSK Investigational Site Yekaterinburg, Russia

View Trial Details

Completed

Safety, Tolerability, and Immunogenicity of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-005)

NCT01337167

Conditions: Actinomycetales Infections, Bacterial Infections, Bacterial Infections and Mycoses, +34 more
Locations: Not specified

View Trial Details